Biovica: Signs its fourth tier-1 oncology Master Service Agreement based on DiviTum - Redeye
Bildkälla: Stockfoto

Biovica: Signs its fourth tier-1 oncology Master Service Agreement based on DiviTum - Redeye

The MSA (Master Service Agreement) include a first study work order of SEK 4m in sales from late 2025 to 2028, suggesting that DiviTum will be used in a more extensive clinical study.

The MSA (Master Service Agreement) include a first study work order of SEK 4m in sales from late 2025 to 2028, suggesting that DiviTum will be used in a more extensive clinical study.
Börsvärldens nyhetsbrev